Alkem Laboratories Limited has informed the Exchange about Transcript
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Labs reported FY25 revenue of Rs. 12,964 crore (up 2.3% YoY) with EBITDA margin expanding to 19.4% from 17.7% last year, and net profit up 20.6% to Rs. 2,165 crore. Q4 revenue grew 7.1% to Rs. 3,144 crore with India sales up 8.1% and net profit at Rs. 306 crore. Management guided FY26 EBITDA margins to remain stable at ~19.5%, with R&D spend rising to ~5% of revenue, CAPEX of Rs. 700-750 crore, and tax rate of 13-15%. The company targets 100 bps outperformance vs Indian pharma market, mid-single-digit US growth, and mid-teens growth in rest of world. Biosimilar CDMO plant (Enzene US) is on track to start revenue in Q2 FY26, targeting Rs. 100 crore this year and Rs. 450-500 crore at full capacity in 3 years. New MedTech acquisitions (Bombay Ortho, Adroit Biomed, Exactech licensing) will add Rs. 100-125 crore in operating losses combined. Cash balance stands at Rs. 46.2 billion.
The stable 19.5% margin guidance despite new business investments signals operational discipline, though the Rs. 100-125 crore drag from CDMO/MedTech ramp-up could weigh on near-term profitability. Strong domestic outperformance target and improving US trajectory are positives, but investors should watch the slow margin expansion pace and the timeline for new businesses to contribute meaningfully.